T Cell Immunoreceptor with Immunoglobulin and ITIM domains (TIGIT) is an immune checkpoint receptor expressed on the surface of cytotoxic, memory and regulatory T cells (Tregs) as well as natural killer (NK) cells. TIGIT binds strongly to CD155 (PVR) and weakly to CD112 (Nectin-2). TIGIT suppresses immune activation on cytotoxic T cells and NK cells. In the normal immune system, the suppressive effect of TIGIT is counterbalanced by the immune-activating receptor CD226 (DNAM1), which competes with TIGIT to bind CD155 and CD112. The inhibitory signal provided by TIGIT overpowers the ability of CD226 to stimulate T cell activation. Tumour cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction. Recently, a high-affinity receptor of the ligand CD112/Nectin-2, called CD112R/PVRIG has been described and may become a new attractive cancer immunotherapy target.
LIT: Identification of CD112R as a novel checkpoint for human T cells: Y. Zhu, et al.; J. Exp. Med. 213, 167 (2016) • Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer: H. Stamm, et al.; Mamm. Genome 29, 694 (2018)
Biologically Active TIGIT, CD112R and CD155 Proteins
See all Biologically Active TIGIT Proteins here: AG-40B-0162 and ANC-556.
See all Biologically Active CD112R Proteins here.
See all Biologically Active CD155 Proteins here.
VALIDATED Antibodies for TIGIT, CD112R and CD155 Research
See all VALIDATED Antibodies for TIGIT Research here.
See all VALIDATED Antibodies for CD112R Research here.
See all VALIDATED Antibodies for CD155 Research here: ANC-255 and ANC-350.
Originally posted on adipogen.com/tigit-cd155-cd112-cd226-network/
Caltag Medsystems is the distributor of Adipogen products in the UK and Ireland. If you have any questions about these products, please contact us.